Related Experiment Videos
Botulinum toxin in neuro-urological disorders
Wolfgang H Jost1, Markus Naumann
1Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany. jost.neuro@dkd-weisbaden.de
Summary
Botulinum toxin shows promise in urology for conditions like detrusor sphincter dyssynergia and overactivity, but more research is needed. Current evidence is insufficient for widespread adoption, requiring further controlled studies.
Area of Science:
- Urology
- Neurology
- Pharmacology
Background:
- Botulinum toxin has been utilized in urological practice since the late 1980s.
- Its therapeutic role remains under investigation, lacking definitive establishment.
- Existing studies primarily focus on detrusor sphincter dyssynergia (DSD) and detrusor overactivity (hyperreflexia).
Purpose of the Study:
- To review the current evidence and established indications for botulinum toxin in urology.
- To identify the need for further research to solidify its therapeutic applications.
- To assess the current status of botulinum toxin use in clinical urological practice.
Main Methods:
- Review of existing literature on botulinum toxin in urology.
- Analysis of success rates reported in studies on DSD and detrusor overactivity.
- Identification of potential and investigated urological indications beyond DSD and hyperreflexia.
Main Results:
- Success rates for botulinum toxin in DSD range from 58% to 88%.
- Approximately 80% success rates are reported for detrusor overactivity.
- Potential applications include motor/sensory urge, urethrospasm, pelvic floor spasticity, neobladder, and chronic prostatic pain.
Conclusions:
- Further controlled studies with defined populations and validated outcomes are essential.
- Long-term data on repeated botulinum toxin injections are currently lacking.
- Botulinum toxin application in urology should be limited to experienced practitioners at this time.